Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis

Dermira secures FDA fast track status for lebrikizumab in atopic dermatitis

Source: 
Pharmaceutical Business Review
snippet: 

Dermira has secured fast track designation from the US Food and Drug Administration (FDA) for lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.